Skip to main content

Table 1 Baseline demographics and disease characteristics

From: Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma

Characteristic, n (%)

N = 57

Age, years, median (range)

32.0 (19.0–77.0)

Sex, n (%)

 Male

24 (42.1)

 Female

33 (57.9)

Race, n (%)

 White

44 (77.2)

 Black or African American

8 (14.0)

 Asian

1 (1.8)

 Pacific Islander

3 (5.3)

 Other

1 (1.8)

ECOG performance status, n (%)

 0

32 (56.1)

 1

23 (40.4)

 2

2 (3.5)

Hodgkin lymphoma classification, n (%)

 Classical nodular sclerosis

52 (91.2)

 Classical mixed cellularity

3 (5.3)

 Other

2 (3.5)

Stage at diagnosis, n (%)

 I

2 (3.5)

 II

20 (35.1)

 III

18 (31.6)

 IV

17 (29.8)

Number of previous regimens, median (range)

4 (1–17)

Previous treatment, n (%)

 AHSCT

38 (66.7)

 Gemcitabine-containing regimen

32 (56.1)

 Vinorelbine-containing regimen

23 (40.4)

 Vinblastine-containing regimen

55 (96.5)

Disease progression during previous therapy, n (%)

38 (66.7)

Time from diagnosis to first recurrence/relapse, months, median (range)

11.1 (0.6–80.0)

Time from diagnosis to most recent recurrence/relapse, months, median (range)

38.9 (7.0–221.4)

  1. Unless otherwise noted, all data are presented as n (%)
  2. AHSCT autologous hematopoietic stem cell transplantation, ECOG Eastern Cooperative Oncology Group